We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Patients Who Survive COVID-19 May Have Long-Term Brain Deficits

By HospiMedica International staff writers
Posted on 05 Jun 2020
To date, the focus on COVID-19 patients has been more on keeping them alive and less on examining the impact the disease on their long-term health, although neurological issues in patients who suffer from COVID-19 call for better assessments to shape treatments.

Dr. More...
Majid Fotuhi, MD, PhD, a Harvard- and Johns Hopkins-trained neurologist and neuroscientist, has warned about neurological issues in patients who suffer from COVID-19 and is encouraging more study of the neurological effects of the disease to promote better treatments.

According to Fotuhi, medical director of NeuroGrow Brain Fitness Center, COVID-19’s neurological manifestation can be grouped into three stages. In NeuroCovid Stage I, the virus damage is limited to epithelial cells of nose and mouth. In NeuroCovid Stage II, patients may experience blood clots in their brain or have auto-antibodies that damage their peripheral nerves and muscles. In this stage, the virus can trigger a flood of inflammatory markers, called cytokine storm, which begin in the lungs and travel throughout all body organs. This may lead to blood clots resulting in a series of strokes that can kill neurons. In NeuroCovid Stage III, the blood brain barrier, a protective insulation in blood vessels of the brain, is damaged and patients may develop seizures or encephalopathy. In this rare late stage, the virus particles themselves may invade the brain directly, including the brain region that controls breathing.

Fotuhi has pointed out that many patients with COVID-19 may have no noticeable neurological symptoms at first; but in some cases, patients may present with neurological symptoms even before they have fever, cough, or shortness of breath. He stresses that having an MRI while at the hospital will be an important tool in developing an optimal treatment strategy for these patients. In addition, patients will need to be monitored in a few months after their hospitalization as they may have new symptoms not experienced early in their disease process.

“Our experience with other forms of respiratory viruses that affect the brain suggest that in the long-term patients may develop depression, insomnia, Parkinson’s disease, memory loss, or accelerated aging in the brain,” said Fotuhi.



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Desk Aneroid Sphyg
Diagnostix 750D+
New
Gas Analyzer
GE SAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.